- Home
- SINT vs KZIA Comparison
SINT vs KZIA Comparison
Compare SINT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SINT
- KZIA
- Stock Information
- Founded
- SINT 1996
- KZIA 1994
- Country
- SINT United States
- KZIA Australia
- Employees
- SINT N/A
- KZIA N/A
- Industry
- SINT Medical/Dental Instruments
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SINT Health Care
- KZIA Health Care
- Exchange
- SINT Nasdaq
- KZIA Nasdaq
- Market Cap
- SINT 10.9M
- KZIA 9.0M
- IPO Year
- SINT 2014
- KZIA 1999
- Fundamental
- Price
- SINT $4.17
- KZIA $7.20
- Analyst Decision
- SINT Strong Buy
- KZIA Strong Buy
- Analyst Count
- SINT 1
- KZIA 3
- Target Price
- SINT $25.00
- KZIA $16.00
- AVG Volume (30 Days)
- SINT 119.1K
- KZIA 299.1K
- Earning Date
- SINT 11-11-2025
- KZIA 11-14-2025
- Dividend Yield
- SINT N/A
- KZIA N/A
- EPS Growth
- SINT N/A
- KZIA N/A
- EPS
- SINT N/A
- KZIA N/A
- Revenue
- SINT $1,861,000.00
- KZIA $1,549,158.00
- Revenue This Year
- SINT N/A
- KZIA N/A
- Revenue Next Year
- SINT $87.50
- KZIA $49.25
- P/E Ratio
- SINT N/A
- KZIA N/A
- Revenue Growth
- SINT N/A
- KZIA 248983.08
- 52 Week Low
- SINT $1.71
- KZIA $2.86
- 52 Week High
- SINT $8.60
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- SINT 49.00
- KZIA 43.08
- Support Level
- SINT $3.72
- KZIA $6.20
- Resistance Level
- SINT $4.23
- KZIA $7.61
- Average True Range (ATR)
- SINT 0.41
- KZIA 0.48
- MACD
- SINT -0.11
- KZIA -0.06
- Stochastic Oscillator
- SINT 23.03
- KZIA 47.57
About SINT SiNtx Technologies Inc.
SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.